Ferenc Martenyi

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi [Three paradigms in the treatment of posttraumatic stress disorder]
    Ferenc Martenyi
    Eli Lilly Regional Medical Center, BECS, Ausztria
    Neuropsychopharmacol Hung 7:11-21. 2005
  2. ncbi Fluoxetine in the acute treatment and relapse prevention of combat-related post-traumatic stress disorder: Analysis of the veteran group of a placebo-controlled, randomized clinical trial
    Ferenc Martenyi
    Eli Lilly Area Medical Center, Kölblgasse 8 10, Vienna A 1031, Austria
    Eur Neuropsychopharmacol 16:340-9. 2006
  3. ncbi Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia
    Ferenc Martenyi
    Lilly Corporate Center, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Eur Child Adolesc Psychiatry 19:57-66. 2010
  4. ncbi Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study
    Ferenc Martenyi
    Lilly Research Laboratories, Vienna, Austria
    J Clin Psychopharmacol 27:166-70. 2007
  5. ncbi Fluoxetine versus placebo in posttraumatic stress disorder
    Ferenc Martenyi
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind. 46285, USA
    J Clin Psychiatry 63:199-206. 2002
  6. ncbi Parasitosis, dopaminergic modulation and metabolic disturbances in schizophrenia: evolution of a hypothesis
    Tamas Treuer
    Neuroscience Research, Area Medical Center Vienna, Eli Lilly Regional GmbH, Venna, Austria
    Neuro Endocrinol Lett 28:535-40. 2007
  7. ncbi Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes
    Mauricio Tohen
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Br J Psychiatry 192:135-43. 2008
  8. ncbi Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
    Sandeep T Patil
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Nat Med 13:1102-7. 2007
  9. ncbi Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia
    Peng Yu
    Eli Lilly and Company, Indianapolis, IN, USA
    J Alzheimers Dis 32:373-85. 2012
  10. ncbi Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor
    Patrick C May
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Indiana 46285, USA
    J Neurosci 31:16507-16. 2011

Collaborators

Detail Information

Publications10

  1. ncbi [Three paradigms in the treatment of posttraumatic stress disorder]
    Ferenc Martenyi
    Eli Lilly Regional Medical Center, BECS, Ausztria
    Neuropsychopharmacol Hung 7:11-21. 2005
    ....
  2. ncbi Fluoxetine in the acute treatment and relapse prevention of combat-related post-traumatic stress disorder: Analysis of the veteran group of a placebo-controlled, randomized clinical trial
    Ferenc Martenyi
    Eli Lilly Area Medical Center, Kölblgasse 8 10, Vienna A 1031, Austria
    Eur Neuropsychopharmacol 16:340-9. 2006
    ..93 (3.54) and 5.48 (3.66)]. The risk of relapse in the placebo arm was significantly greater than in the fluoxetine arm (log-rank test chi 2 = 4.090, df = 1, p = 0.048). Fluoxetine was well tolerated at a mean daily dose of 65 mg...
  3. ncbi Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia
    Ferenc Martenyi
    Lilly Corporate Center, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Eur Child Adolesc Psychiatry 19:57-66. 2010
    ..Atomoxetine treatment may be associated with a numerically higher incidence of anorexia, somnolence, abdominal pain and nausea, as well as statistically greater losses in body weight...
  4. ncbi Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study
    Ferenc Martenyi
    Lilly Research Laboratories, Vienna, Austria
    J Clin Psychopharmacol 27:166-70. 2007
    ..9), and -36.6 (25.7) in the 20-mg fluoxetine, 40-mg fluoxetine, and placebo arms, respectively. Placebo response rate was substantially higher in this study than in a previously published fluoxetine trial of posttraumatic stress disorder...
  5. ncbi Fluoxetine versus placebo in posttraumatic stress disorder
    Ferenc Martenyi
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind. 46285, USA
    J Clin Psychiatry 63:199-206. 2002
    ..CONCLUSION: Fluoxetine is effective and well tolerated in the treatment of PTSD. Most PTSD patients will respond satisfactorily at doses in the upper normal range for the usual antidepressant doses of fluoxetine...
  6. ncbi Parasitosis, dopaminergic modulation and metabolic disturbances in schizophrenia: evolution of a hypothesis
    Tamas Treuer
    Neuroscience Research, Area Medical Center Vienna, Eli Lilly Regional GmbH, Venna, Austria
    Neuro Endocrinol Lett 28:535-40. 2007
    ..We believe this model may well open up new avenues of research in the discovery of drugs to counteract schizophrenia...
  7. ncbi Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes
    Mauricio Tohen
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Br J Psychiatry 192:135-43. 2008
    ..Combinations of olanzapine and carbamazepine are often used in clinical practice in the management of mania...
  8. ncbi Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
    Sandeep T Patil
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Nat Med 13:1102-7. 2007
    ..These data suggest that mGlu2/3 receptor agonists have antipsychotic properties and may provide a new alternative for the treatment of schizophrenia...
  9. ncbi Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia
    Peng Yu
    Eli Lilly and Company, Indianapolis, IN, USA
    J Alzheimers Dis 32:373-85. 2012
    ..Overall, the combination of MRI, ApoE, and cognitive scores provided the best trade-off between cost and time compared with other biomarker combinations for patient recruitment in clinical trial...
  10. ncbi Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor
    Patrick C May
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Indiana 46285, USA
    J Neurosci 31:16507-16. 2011
    ..The magnitude and duration of central Aβ reduction obtainable with BACE1 inhibition positions this protease as a tractable small-molecule target through which to test the amyloid hypothesis in man...